| 15.8509 -0.379 (-2.34%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.29  |
1-year : | 21.49 |
| Resists | First : | 17.37 |
Second : | 18.39 |
| Pivot price | 17.01 |
|||
| Supports | First : | 15.71 | Second : | 13.07 |
| MAs | MA(5) : | 16.15 |
MA(20) : | 17.19 |
| MA(100) : | 18.26 |
MA(250) : | 16.85 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 8.4 |
D(3) : | 7.2 |
| RSI | RSI(14): 35.5 |
|||
| 52-week | High : | 25.87 | Low : | 14.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BIS ] has closed above bottom band by 10.2%. Bollinger Bands are 7.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.06 - 16.15 | 16.15 - 16.22 |
| Low: | 15.49 - 15.62 | 15.62 - 15.72 |
| Close: | 15.66 - 15.85 | 15.85 - 16.01 |
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Sun, 13 Jul 2025
Tonix Pharmaceuticals ($TNXP) Skyrockets 284% in 2025: Earnings Catalysts.... - Investing.com India
Wed, 14 May 2025
Top Performing Leveraged/Inverse ETFs: 05/11/2025 - ETF Trends
Tue, 19 Nov 2024
Top Performing Leveraged/Inverse ETFs: 11/17/2024 - ETF Trends
Wed, 05 Jan 2022
2021 Year in Review: Swelling the Ranks of the Nasdaq Biotechnology Index™ - Nasdaq
Wed, 22 Dec 2021
Top Biotechnology Indexes in the U.S. and How to Invest in Them - Nasdaq
Wed, 29 May 2019
Top Healthcare ETFs Right Now • Updated Daily - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|